Navigation Links
Insmed Announces Additional Information in Compliance With NASDAQ Rules
Date:3/18/2008

be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
2. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
3. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
4. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
5. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
6. Insmed to Appeal Delisting Notification From Nasdaq
7. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
8. Insmed Appoints Dennis M. Lanfear to Board Of Directors
9. Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Marteks lifesDHA
10. Visionsense Announces Food and Drug Administration (FDA) 510(k) Clearance for VSII - Visionsense Stereoscopic Vision System
11. OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNAs, Including Its Phase III Compound Bevasiranib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Hospital Energy Performance Service can help ... energy efficiency by 25% or more ... The service is available from Environmental Health ... and engineering consulting firm."Healthcare facilities are heavy energy users and ...
... Inc., a privately-held specialty pharmaceutical company, announced today that ... evaluate EVK-001 for the treatment of adults with symptoms ... delayed emptying of the stomach into the intestine following ... is an important cause of gastroparesis, but other identified ...
... Mass., May 5 Syrinx Consulting Corporation ... that delivers easy-to-use .Net and SharePoint applications ... contract for approximately $100,000 with a leading biopharmaceutical company ... migrating thousands of users and gigabytes of data from ...
Cached Biology Technology:New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 3Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services 2
(Date:4/15/2014)... American Association of Anatomists (AAA) is honored to announce ... presented during the Closing Awards Ceremony being held at ... at 7:30 p.m. during AAA,s 2014 Annual Meeting at ... winners are: , Henry Gray/Elsevier Distinguished Educator ... of Medicine at Mount Sinai, Past-President of the American ...
(Date:4/15/2014)... In recent years, it has become clear that ... previously assumed. In addition to the well-known building ... variations play an important role. Scientists now assume ... form a second layer of information that extends ... are rather like umlauts that extend the standard ...
(Date:4/14/2014)... subarctic forest moths in Finnish Lapland suggests that scientists ... animals and plants because much of the harm is ... 80 moth species and found that 90 percent of ... period, from 1978 to 2009. During that time, average ... Fahrenheit, and winter precipitation increased as well. , "You ...
Breaking Biology News(10 mins):American Association of Anatomists 2014 award winners 2German Research Foundation approves new priority program in the life sciences 2Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3
... They may never win an Oscar, but scientists at ... have developed techniques for creating accurate movies of biological ... now. Biological and organic molecules in solution ... of salt or metals since they are constantly moving ...
... increased risk of wheezing in the chest if they take part ... shown in a new study using data from the Norwegian Mother ... (NIPH). The results come from a study of ... children took part in baby swimming from 0-6 months of age. ...
... is available in French . , ... Management, the private bankers Lombard Odier Darier Hentsch & ... at EPFL dedicated to sustainable development. The chair is ... fundamental and social sciences in the environmental domain. ...
Cached Biology News:Argonne scientists develop techniques for creating molecular movies 2Possible link between baby swimming and breathing problems in children 2EPFL Research Day 2008, in the presence of Al Gore 2EPFL Research Day 2008, in the presence of Al Gore 3
... strains are K-12 derivatives that have mutations ... glutathione reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielded ... host even though overall expression levels were ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... Cy3 Ab Labeling Kit, 1 kit. ... CyDye fluorescent dyes. Conjugations are carried ... within 1 h. Dyes are packaged ... ensure consistent labelings. Category: Blotting & ...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: